|
Mechanismcaspase 3 activators [+1] |
|
|
|
|
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
评价用福大赛因注射液光动力治疗完全或不完全梗阻原发性食管癌患者有效性安全性的开放多中心II期临床试验
[Translation] An open multicenter phase II clinical trial to evaluate the effectiveness and safety of photodynamic therapy with forsine injection in patients with complete or incomplete obstruction of primary esophageal cancer
主要目的:评价福大赛因注射液对于改善食管阻塞和吞咽困难症状的疗效。 次要目的:评价福大赛因注射液治疗前后肿瘤病灶缩小情况;评价福大赛因注射液治疗前后生活质量改善情况;评价福大赛因注射液治疗的安全性及潜在操作风险的控制。
[Translation] Primary objective: To evaluate the efficacy of Fosdaigin injection in improving esophageal obstruction and dysphagia. Secondary objectives: To evaluate the reduction of tumor lesions before and after Fosdaigin injection treatment; to evaluate the improvement of quality of life before and after Fosdaigin injection treatment; to evaluate the safety of Fosdaigin injection treatment and the control of potential operational risks.
Safety Study of Photodynamic Therapy Using Photocyanine Injection in Treating Patients With Malignant Tumors
The purpose of this study is to determine the safety and maximum tolerated dose of Photocyanine injection in photodynamic therapy of malignant tumor (especially skin cancer and esophageal cancer).
Projected accrual: A total of 18-24 patients will be accrued for this study.
100 Clinical Results associated with Fujian Longhua Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with Fujian Longhua Pharmaceutical Co., Ltd.
100 Deals associated with Fujian Longhua Pharmaceutical Co., Ltd.
100 Translational Medicine associated with Fujian Longhua Pharmaceutical Co., Ltd.